CSL Behring cannot provide a guarantee that expanded access will be available for every experimental medicine. Even if such a program is offered CSL Behring cannot guarantee that an experimental medicine will be available to a particular patient. The early access will cease if clinical trials or regulatory assessment determines the product does not demonstrate a positive risk benefit for patients. Once the experimental medicine is approved and commercially available in the US, early access will no longer be available.